220 
DR. FREDRICKSON: Mr. Hutt. 
MR. HUTT: I think we need clarification. It is an accurate statement, 
then, that it does not meet the current, existing Guidelines? 
DR. ADAMS: That would be correct, Peter, except that this research, I 
assume, was undertaken with the understanding that there would be some change 
in the definition. You must bear in mind that there have been many defi- 
nitions offered for recombinant DNA research, many of them in legislative 
proposals, and I assume the investigator felt that those definitions were 
really more pertinent than was the case in the present definition of recom- 
binant DNA, not in the revision but in the original. I think it is a judg- 
ment by the investigator. 
MR. HUTT: I just want a clarification. It would meet the new defini- 
tion that is not yet adopted by the NIH. It would not meet the old Guide- 
lines or the current Guidelines? That is all I wanted to clarify. Is it in 
all other respects — well, it couldn't be. 
DR. GINSBERG: In most universities with which I am familiar, the 
biosafety committee oversees all recombinant DNA research whether it is 
supported by NIH or private funds. So I would assume that if he is at a 
university with a biosafety committee, that is is probably being overviewed 
by them, anyway. 
DR. ADAMS: He is in a university that has a very active biohazards 
committee . 
DR. FREDRICKSON: I think that we will go on now to the next witness, 
who is Mr. Leslie Dach . 
MS. SIMRING: May I just respond to that for a moment? 
DR. FREDRICKSON: Ms. Simring, if you please, rise and do it speedily. 
MS. SIMRING: We might question, then, the efficacy of a biohazards 
committee in its oversight if it permitted the research to go ahead not 
under the voluntary compliance acceded to by Miles Laboratories with these 
June '76 Guidelines. Where does the responsibility lie? Miles Laboratories 
is undertaking, per se, the research. It is under its aegis, it is under 
its funding at the University of Rochester Medical Center, and we have to 
ask where does the responsibility therefore lie? 
DR. FREDRICKSON: All right, Mr. Dach. 
MR. DACH: With all due respect to the Recombinant DNA Advisory Commit- 
tee, I think that Section IV is really a completely inadequate section. It 
is simply too vague to support any enforcement, and if we look more closely 
at the manpower staff that is allotted to this kind of job, that also bears 
[ 424 ] 
